脂必泰联合瑞舒伐他汀治疗冠心病血脂异常患者的效果

Effect of Zhibitai combined with rosuvastatin on patients with dyslipidemia of coronary heart disease

目的观察脂必泰联合瑞舒伐他汀对冠心病血脂异常患者的降脂效果及对颈动脉中内膜厚度(IMT)的影响。方法将我院2017年1月至2017年6月收治的冠心病合并高脂血症患者90例随机分为对照组与治疗组,各45例。治疗组给予脂必泰联合瑞舒伐他汀治疗,对照组给予瑞舒伐他汀治疗。比较两组患者治疗前1个月及治疗6个月后的血脂水平及治疗前、治疗6、12个月后的IMT。结果治疗后,两组患者的血清TC、TG、LDL-C及脂蛋白a水平均低于治疗前,治疗组血清TC、LDL-C及脂蛋白a水平均低于对照组(P<0.05);两组患者的血清HDL-C水平均高于治疗前(P<0.05)。治疗6、12个月后,两组患者IMT均低于治疗前,且治疗12个月后治疗组低于对照组(P<0.05)。结论瑞舒伐他汀治疗基础上加用脂必泰胶囊能够更加有效地改善冠心病血脂异常患者的血脂水平,抑制IMT增厚,值得推广应用。

Objective To observe the effect of Zhibitai combined with resuvastatin on reducing lipid and carotid intimamedia thickness (IMT) in patients with dyslipidemia of coronary heart disease. Methods Ninety patients with coronary heart disease and hyperlipidemia admitted in our hospital from January 2017 to June 2017 were randomly divided into control group and treatment group, with 45 cases in each group. The treatment group was treated with Zhibitai combined with rosuvastatin, while the control group was treated with rosuvastatin. The blood lipid levels at 1 month before treatment and at 6 months after treatment, and IMT before treatment and at 6, 12 months after treatment were compared between the two groups. Results After treatment, the levels of serum TC, TG, LDL-C and lipoprotein a in the two groups were lower than those before treatment, and the levels of serum TC, LDL-C and lipoprotein a in the treatment group were lower than those in the control group (P<0.05);the serum HDL-C levels of the two groups were higher than those before treatment (P<0.05). After 6 and 12 months of treatment, the IMT of both groups were lower than those before treatment, and the IMT of the treatment group was lower than that of the control group after 12 months of treatment (P<0.05). Conclusion On the basis of rosuvastatin treatment, Zhibitai can effectively improve the blood lipid levels and inhibit the thickening of IMT in patients with dyslipidemia of coronary heart disease, which is worthy of popularization and application.